Answers are grounded in this paper and cite their sources.
Background and Objectives: Hepatitis B virus (HBV) reactivation is a potentially life-threatening complication in patients receiving chemotherapy and immunosuppressive therapy. Real-world data regarding reactivation despite antiviral prophylaxis remain limited. Materials and Methods: We retrospectively evaluated patients with malignancies who received chemotherapy at Kocaeli University Faculty of Medicine Hospital between 2013 and 2017. Demographic characteristics, malignancy type, virological markers, laboratory findings, chemotherapy regimens, antiviral prophylaxis strategies, and HBV reactivation rates were analyzed. Results: A total of 294 patients were included in this study, of whom 18 (6.1%) experienced HBV reactivation. Reactivation was significantly more common in patients with hematologic malignancies (11.1%) than in patients with solid tumors (3.2%). Bone marrow transplantation was associated with a higher observed frequency of HBV reactivation. HBV reactivation was observed in a subset of patients receiving antiviral prophylaxis. Delayed initiation of antiviral treatment and irregular antiviral use were documented in some patients who developed HBV reactivation. Conclusions: Malignancies and intensive immunosuppressive therapies were associated with an increased risk of HBV reactivation despite prophylactic strategies. The results of our study also highlight the importance of HBV screening before chemotherapy, timely initiation of potent antiviral prophylaxis, and extended post-treatment monitoring in high-risk populations.
No takes yet. Share an insight, caveat, or question.
Erdekli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: